Georgetown University's Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, ...

SHENZHEN, China, Sept. 17, 2025 /PRNewswire/ -- MagicRNA, a clinical-stage biotechnology company pioneering in vivo CAR T-cell therapies, today announced the publication of the world's first clinical ...

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for ...

Funding includes $8.5M from an oversubscribed seed financing with up to $37.3M in non-dilutive investment from The Japan Agency for Medical Research and Development (AMED), underscoring Japan’s ...

As people age, their immune system function declines. T cell populations become smaller and can't react to pathogens as quickly, making people more susceptible to a variety of infections. To try to ...

At the recent American Society of Hematology annual meeting, researchers presented preclinical data examining how transdifferentiation between hematopoietic lineages -- driven by LMO2 expression and ...

In order to reprogram readily available cells into specific immune cells that fight various diseases, one must know the ...

Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute. In vivo CAR T-cell therapy could drastically ...